Further Review of Aspirin in the Treatment of Kawasaki Disease
Zhaoling Shi
Shaanxi University of Chinese Medicine, Xi’an, 712000, China.
Kai-Sheng Hsieh
Children’s Hospital, China Medical University, Taichung, Taiwan, China.
Hong Wang
Shenging Hospital of China Medical University, China.
Xiaodong Yang
Children’s Hospital of Shanghai Jiao Tong University, China.
Ling Zhang
Changzhi Medical Collage, Changzhi, Shanxi, China.
Xiangyue Kong
Level 19 Nursing Class 1986, Xi'an Medical University, Xi'an, China.
Jianying Feng
Children's Hospital of Shaanxi Provincial People's Hospital, Xi’an, 710068, China.
Juyan Wang
Children's Hospital of Shaanxi Provincial People's Hospital, Xi’an, 710068, China.
Fuyong Jiao *
Children's Hospital of Shaanxi Provincial People's Hospital, Xi’an, 710068, China.
*Author to whom correspondence should be addressed.
Abstract
Aspirin only prevents platelets from accumulating in the dilated coronary arteries and prevents thrombosis, thus minimizing thrombosis as much as possible, and does not shrink the already dilated coronary artery tumor. Therefore, it plays an important role in the treatment of Kawasaki disease, but it is not the cause of treatment. Aspirin is common in the treatment of Kawasaki disease in children, and its effect is to reduce acute inflammatory response and alleviate platelet aggregation. Aspirin has been used to treat Kawasaki disease for more than 50 years. Since 1961, when Kawasaki discovered the first reported case of hemorrhagic shock caused by aspirin in children with Kawasaki disease, we need to re-explores the use of aspirin in the treatment of Kawasaki disease.
Keywords: Aspirin, Kawasaki disease, coronary artery damage